Radcliffe Capital Management’s MoonLake Immunotherapeutics MLTX Stock Holding History

Radcliffe Capital Management’s Portfolio MLTX Stock Details MLTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q1	–	Sell	-25,130	Closed	-$249K	–	1222
2021 Q4	$249K	Sell	25,130 -1	-0%	-$10	0.01%	1012
2021 Q3	$248K	Hold	25,131	–	–	0.01%	862
2021 Q2	$260K	Buy	25,131 +5,131	+26%	+$52.1K	0.01%	886
2021 Q1	$205K	Hold	20,000	–	–	0.01%	673
2020 Q4	$227K	Buy	+20,000	New	+$212K	0.01%	339

Other funds holding MLTX

CAM

Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

6CM

683 Capital Management New York $1.92B AUM 85.52% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return

SCA

STALEY CAPITAL ADVISERS Pittsburgh, Pennsylvania $2.36B AUM 23.72% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

BCM

Beryl Capital Management Redondo Beach, California $110M AUM 317.92% 1-Year Est. Return

AWG

Alpha Wave Global New York $791M AUM 113.77% 1-Year Est. Return

Radcliffe Capital Management's MLTX Position: Q1 2022 in Review

Radcliffe Capital Management sold out of MoonLake Immunotherapeutics (MLTX) in Q1 2022, closing a stake of 25,130 shares — an estimated $249K sold.

Radcliffe Capital Management first reported a position in MLTX in Q4 2020 and held it in 5 quarters. The position peaked at $260K in Q2 2021. 27 funds tracked by Wall St. Rank hold MLTX as of Q1 2022.

Radcliffe Capital Management reported no remaining MoonLake Immunotherapeutics position as of Q1 2022 after selling out during the quarter.
Radcliffe Capital Management sold 25,130 MoonLake Immunotherapeutics shares in Q1 2022, an estimated $249K.
Radcliffe Capital Management first reported a position in MoonLake Immunotherapeutics in Q4 2020 and held it in 5 quarters.
Radcliffe Capital Management's MoonLake Immunotherapeutics position peaked at $260K in Q2 2021.
27 funds tracked by Wall St. Rank held MoonLake Immunotherapeutics as of Q1 2022.

Based on Radcliffe Capital Management's 13F filing for Q1 2022, filed 16 May 2022.